Malvern’s Recro Pharma is already preparing for the potential commercial launch of its highly anticipated new drug with a $35.9 million public stock offering, writes John George for the Philadelphia Business Journal.

The specialty pharmaceutical company was aiming to sell $6.5 million of its common stock shares at $6 per share, with the offering having closed last Friday. It intends to utilize the estimated $35.9 million in proceeds to cover any expenses related to the filing of its new drug application for IV meloxicam and to prepare for its potential commercial launch.

The funds will also be used to fund a third phase-III study to help complete its assessment of the drug.

IV meloxicam is being developed to treat acute postoperative pain in patients resulting from surgery on both soft and hard tissue. The company already posted positive data last month from its second phase-III clinical trial.

“It is challenging to get positive study data in pain,” said Gerri Henwood, president and CEO of Recro Pharma. “It’s a tough area.”

Read more about the public offering in the Philadelphia Business Journal here, and check out previous VISTA Today coverage of Recro Pharma here.